

18351 U.S. PTO
020504Practitioner's Docket No. : MPI03-015P1RNOMNIM**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

031356 U.S.PTO
10/772636
020504**NEW APPLICATION TRANSMITTAL**

Transmitted herewith for filing is the patent application of
Inventor(s): Louise M. Kelly, Joseph M. Carroll, Deborah Farlow, and Aileen Healy

For: METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING
9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544,
7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947,
53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 or 5014

1. Type of Application

This new application is for a(n)

Original (nonprovisional)
 Design
 Plant
 Divisional.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. EV400464565US

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature 
Sean Hunziker
(type or print name of person certifying)

Date: February 5, 2004

***WARNING:** *Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).*

"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. : MPI03-015P1RNOMNIM

- Continuation.
- Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)

- The new application being transmitted claims the benefit of U.S. Provisional Application Serial No. 60/445,241, filed on February 5, 2003, of U.S. Provisional Application Serial No. 60/448,389, filed on February 18, 2003, of U.S. Provisional Application Serial No. 60/456,320, filed on March 20, 2003, of U.S. Provisional Application Serial No. 60/460,279, filed on April 3, 2003, of U.S. Provisional Application Serial No. 60/465,924, filed on April 28, 2003, of U.S. Provisional Application Serial No. 60/470,052, filed on May 13, 2003, of U.S. Provisional Application Serial No. 60/498,106, filed on August 26, 2003, of U.S. Provisional Application Serial No. 60/500,179, filed on September 4, 2003, of U.S. Provisional Application Serial No. 60/502,909, filed on September 15, 2003, of U.S. Provisional Application Serial No. 60/510,351, filed on October 10, 2003, and of U.S. Provisional Application Serial No. 60/512,380, filed on October 17, 2003.

3. Maintenance of Copendency of Prior Application

- A. Extension of time in prior application**
- B. Conditional Petition for Extension of Time in Prior Application**

(complete this item, if previous item not applicable)

- A conditional petition for extension of time is being filed in the pending **prior** application.
- A **copy** of the conditional petition filed in the prior application is attached.

4. Abandonment of Prior Application (*if applicable*)

- Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

Notification in Parent Application of This Filing

- A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

5. Papers Enclosed

Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

161 Pages of Specification, including
156 Pages of Description
4 Pages of Claims
1 Page of Abstract
0 Sheets of Drawings (Figure(s))

The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
 Formal
 Informal

6. Additional Papers Enclosed

Information Disclosure Statement (37 C.F.R. Section 1.98)
 Form PTO-1449 (PTO/SB/08A and 08B)
 Citations
 Declaration of Biological Deposit
 162 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), Diskette containing computer readable form of Sequence Listing (37 CFR Section 1.821(e) and 1.824), and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f))
 Authorization of Attorney(s) to Accept and Follow Instructions from Representative
 Special Comments
 Other: Associate Power of Attorney (2 pages), and Statement of Limited Recognition under 37CFR §10.9(b) for Mario Cloutier (1 page)
 Statement of Limited Recognition under 37CFR 10.9(b) for Mario Cloutier (1 page)

7. Declaration or Oath (including power of attorney)

(6 pages) One unexecuted Combined Declaration and Power of Attorney, a copy of which is enclosed.
 Not Enclosed.

8. Assignment

Assignments of the invention to Millennium Pharmaceuticals, Inc. copies of which
 are enclosed.
 will follow.

9. Fee Calculation (37 C.F.R. Section 1.16)

A. Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a)
Total Claims (37 C.F.R. Section 1.16(c))	22	- 20 =	2	\$18.00	\$36.00
Independent Claims (37 C.F.R. Section 1.16(b))	4	- 3 =	1	\$86.00	\$86.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	No	\$290.00			\$0.00

Filing Fee Calculation \$892.00

Amendment canceling extra claims is enclosed.
 Amendment deleting multiple-dependencies is enclosed.
 Fee for extra claims is not being paid at this time.

10. Method of Payment of Fees

Practitioner's Docket No. : MPI03-015P1RNOMNIM

Check in the amount of \$ _____.
 Charge Account No. 501668 in the amount of \$892.00
A duplicate of this transmittal is attached.

11. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.

37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)

37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)

37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a))

37 C.F.R. Section 1.17 (application processing fees)

37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

12. Instructions as to Overpayment

Credit Account No. 501668.

Refund

February 5, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Mario Cloutier
Mario Cloutier
Limited Recognition Under 37 C.F.R. §10.9(b)
40 Lansdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820

Statement Where No Further Pages Added

This transmittal ends with this page.